Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)
Trial details
- Registry ID
- NCT02577029
- Phase
- Phase 2
The FDA approved tenofovir disoproxil (Viread) on 26 Oct 2001.
Drug identity checked against registry records
Also recorded as Viread
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)NCT02577029 | Arrowhead Pharmaceuticals | Phase 2 | Terminated | 2016-12Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2001-10-26Day | tenofovir disoproxil | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA021356", "applicant_as_listed_by_fda": "GILEAD SCIENCES INC", "brand_names": ["VIREAD"], "active_ingredients": ["TENOFOVIR DISOPROXIL FUMARATE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20011026", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |